Myelofibrosis
Conditions
Brief summary
To assess the frequency and types of adverse events and serious adverse events reported in subjects receiving ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone.
Interventions
Sponsors
Incyte Corp.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the frequency and types of adverse events and serious adverse events reported in subjects receiving ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone. | — |
Countries
Poland
Outcome results
None listed